Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 50% Off
/Free Sign Up
 0
Get a powerful boost to your portfolio: August's freshest AI-picked stocks
Pick Stocks with AI
Close

Dermavant Sciences Ltd (DRMT_old)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Dermavant Sciences's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Dermavant Sciences historical data, for real-time data please try another search
0.02 0.00    0.00%
04/02 - Closed. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 0.00 - 0.02
Dermavant Sciences 0.02 0.00 0.00%

Dermavant Sciences Ltd Company Profile

 
Get an in-depth profile of Dermavant Sciences Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

48

Equity Type

ORD

Dermavant Sciences Ltd., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics in medical dermatology. The company’s lead product candidate is Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent topical cream that is in Phase III clinical trials for the treatment of psoriasis and atopic dermatitis. Its product candidates in Phase I clinical trials include Cerdulatinib (DMVT-505), a dual inhibitor of the Janus kinase and spleen tyrosine kinase pathways for the treatment of vitiligo as well as other inflammatory skin conditions, such as atopic dermatitis, and Oxybutynin/Pilocarpine (DMVT-504), an investigational oral therapy for the treatment of primary focal hyperhidrosis. The company’s product candidates in the preclinical stage are DMVT-503, a topical DGAT1 inhibitor for the treatment of acne vulgaris, and DMVT-501 (lotamilast), a topical phosphodiesterase type 4 inhibitor that is used as a potential treatment option for atopic dermatitis. Dermavant Sciences Ltd. was formerly known as Roivant Dermatology Ltd. and changed its name to Dermavant Sciences Ltd. in June 2016. The company was founded in 2016 and is based in London, United Kingdom. Dermavant Sciences Ltd. operates as a subsidiary of Roivant Sciences Ltd. As of October 28, 2024, Dermavant Sciences Ltd. operates as a subsidiary of Organon & Co..

Contact Information

Address 11-12 St. James’s Square Suite 1
3rd Floor London, SW1Y 4LB
United Kingdom
Phone 44 20 7400 3347
Fax -
Web www.dermavant.com
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

DRMT_old Comments

Write your thoughts about Dermavant Sciences Ltd
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Apple
Continue with Google
or
Sign up with Email